Company Information


San Francisco, CA, US


Gerald McMahon


Arix Representative

At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC™ (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumor malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.

Harpoon was founded in 2015 by a small team led by Patrick Baeuerle, Ph.D., a pioneer in the development of T cell based cancer therapies, and Luke Evnin, Ph.D., a founder of MPM Capital.